BioTrinity 2010: UK’s Premier Biotech and Investment Conference  

BioTrinity 2010 is UK's Premier Biopartnering and Investment conference and is building on its reputation as Europe's fastest growing partnering conference with more investors than any other UK conference.   BioTrinity takes places from April 12-14  2010 at the Newbury Racecourse, and is expected to attract 650+ delegates in 2010.

BioTrinity 2010 has its own website where you can find out more and register: www.biotrinity.com

Join us as we bring together a critical mass: a multitude of investors, global pharma and innovative R&D companies all within an hour of Heathrow. 40 investment firms, 13 big pharma and over 240 companies from 12 countries in total have already confirmed participation with 9 weeks to go. BioTrinity includes a hand-picked showcase of the UK's best biotech and medtech companies, a vibrant social programme and gold standard private partnering provided by:

BioTrinity is a two day conference with conference programme (panels, workshops and presentations), simultaneous exhibition, and private partnering meetings for all companies involved in the life science industry. 2010 sees the conference move to Newbury Racecourse and will open with the Grand Opening Reception in the Exhibition Hall on the evening of 12th April with the main conference starting 0800 on 13th April. Register now to meet with your peers at this prestigious event.

The "Event of the Year" - BioTrinity 2010:

• Partnering with global pharma / investors
• 40+ presentations by hand-picked R&D companies
• Massively expanded networking hubs
• First class venue at Newbury Racecourse

Exciting Social Programme:

• Grand Opening Reception and Gala Dinner
• Europe's Largest Investor-only Dinner
• Golf Tournament

Projection for BioTrinity 2010

• 650+ delegates from 20 countries
• 1200 partnering meetings
• 60 investment firms from 8 countries
• More than two-thirds of the top 20 global pharma

2009 Statistics

• 500+ delegates from 16 countries
• 750 partnering meetings (up 50%)
• 40 investment firms from 6 countries
• Two-thirds of the top 20 global pharma